Back to All Combinations
KRAS G12D (Emerging)
Intermediate PrognosisGenes Involved
KRAS
Treatment Implications
MRTX1133 and others showing promise. Could transform treatment.
Recommended Treatments
Standard therapy
Clinical trials
Treatments to Avoid
No specific contraindications noted
Study References
MRTX1133 Phase 1
Key Statistics
12.00%
Prevalence in CRC
No
Targetable
Clinical Notes
G12D inhibitors 1-2 years behind G12C.
Information
Category: Emerging Targets
Evidence Level: Level 3
Last Updated: Dec 7, 2025
Related Combinations
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.